Which has higher earnings and valuation, BOLT or RADX?

Bolt Biotherapeutics has higher revenue and earnings than Radiopharm Theranostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bolt Biotherapeutics $7.70M 0.86 -$33.38M -$16.44 N/A Radiopharm Theranostics $1.88M 11.86 -$37.43M N/A N/A

Does the media favor BOLT or RADX?

In the previous week, Bolt Biotherapeutics and Bolt Biotherapeutics both had 1 articles in the media. Radiopharm Theranostics' average media sentiment score of 0.10 beat Bolt Biotherapeutics' score of 0.00 indicating that Radiopharm Theranostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bolt Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Radiopharm Theranostics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer TCRX or BOLT?

In the previous week, TScan Therapeutics had 2 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 3 mentions for TScan Therapeutics and 1 mentions for Bolt Biotherapeutics. TScan Therapeutics' average media sentiment score of 0.00 equaled Bolt Biotherapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TScan Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bolt Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer BOLT or NEUP?

In the previous week, Neuphoria Therapeutics had 2 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 3 mentions for Neuphoria Therapeutics and 1 mentions for Bolt Biotherapeutics. Neuphoria Therapeutics' average media sentiment score of 0.33 beat Bolt Biotherapeutics' score of 0.00 indicating that Neuphoria Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bolt Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neuphoria Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ATOS or BOLT?

In the previous week, Atossa Genetics had 3 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 4 mentions for Atossa Genetics and 1 mentions for Bolt Biotherapeutics. Atossa Genetics' average media sentiment score of 0.19 beat Bolt Biotherapeutics' score of 0.00 indicating that Atossa Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atossa Genetics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bolt Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Bolt Biotherapeutics (BOLT) Competitors

$3.45 -0.06 (-1.71%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$3.52 +0.06 (+1.88%)

As of 10/2/2026 07:55 PM Eastern

Compare

BOLT vs. RADX, TCRX, JSPR, NEUP, and ATOS

Should you buy Bolt Biotherapeutics stock or one of its competitors? Bolt Biotherapeutics's main competitors and comparable companies include Radiopharm Theranostics (RADX), TScan Therapeutics (TCRX), Jasper Therapeutics (JSPR), Neuphoria Therapeutics (NEUP), and Atossa Genetics (ATOS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Bolt Biotherapeutics compare to Radiopharm Theranostics?

Bolt Biotherapeutics (NASDAQ:BOLT) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

86.7% of Bolt Biotherapeutics shares are held by institutional investors. 9.4% of Bolt Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Bolt Biotherapeutics and Bolt Biotherapeutics both had 1 articles in the media. Radiopharm Theranostics' average media sentiment score of 0.10 beat Bolt Biotherapeutics' score of 0.00 indicating that Radiopharm Theranostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bolt Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Radiopharm Theranostics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bolt Biotherapeutics has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.Comparatively, Radiopharm Theranostics has a beta of 1.78, meaning that its share price is 78% more volatile than the broader market.

Bolt Biotherapeutics currently has a consensus target price of $14.50, suggesting a potential upside of 320.29%. Radiopharm Theranostics has a consensus target price of $11.00, suggesting a potential upside of 674.65%. Given Radiopharm Theranostics' stronger consensus rating and higher probable upside, analysts plainly believe Radiopharm Theranostics is more favorable than Bolt Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Bolt Biotherapeutics has higher revenue and earnings than Radiopharm Theranostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bolt Biotherapeutics	$7.70M	0.86	-$33.38M	-$16.44	N/A
Radiopharm Theranostics	$1.88M	11.86	-$37.43M	N/A	N/A

Radiopharm Theranostics has a net margin of 0.00% compared to Bolt Biotherapeutics' net margin of -611.47%. Radiopharm Theranostics' return on equity of 0.00% beat Bolt Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bolt Biotherapeutics	-611.47%	-126.23%	-54.70%
Radiopharm Theranostics	N/A	N/A	N/A

Summary

Radiopharm Theranostics beats Bolt Biotherapeutics on 8 of the 12 factors compared between the two stocks.

How does Bolt Biotherapeutics compare to TScan Therapeutics?

TScan Therapeutics (NASDAQ:TCRX) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

Bolt Biotherapeutics has a net margin of -611.47% compared to TScan Therapeutics' net margin of -1,655.35%. TScan Therapeutics' return on equity of -108.72% beat Bolt Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,655.35%	-108.72%	-54.47%
Bolt Biotherapeutics	-611.47%	-126.23%	-54.70%

In the previous week, TScan Therapeutics had 2 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 3 mentions for TScan Therapeutics and 1 mentions for Bolt Biotherapeutics. TScan Therapeutics' average media sentiment score of 0.00 equaled Bolt Biotherapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TScan Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bolt Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

TScan Therapeutics has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, Bolt Biotherapeutics has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.

Bolt Biotherapeutics has lower revenue, but higher earnings than TScan Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	2.10	-$129.77M	-$0.91	N/A
Bolt Biotherapeutics	$7.70M	0.86	-$33.38M	-$16.44	N/A

TScan Therapeutics presently has a consensus price target of $2.67, suggesting a potential upside of 732.03%. Bolt Biotherapeutics has a consensus price target of $14.50, suggesting a potential upside of 320.29%. Given TScan Therapeutics' higher probable upside, equities analysts plainly believe TScan Therapeutics is more favorable than Bolt Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.13
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are held by institutional investors. 6.3% of TScan Therapeutics shares are held by insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

TScan Therapeutics beats Bolt Biotherapeutics on 8 of the 14 factors compared between the two stocks.

How does Bolt Biotherapeutics compare to Jasper Therapeutics?

Bolt Biotherapeutics (NASDAQ:BOLT) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Jasper Therapeutics has a net margin of 0.00% compared to Bolt Biotherapeutics' net margin of -611.47%. Bolt Biotherapeutics' return on equity of -126.23% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bolt Biotherapeutics	-611.47%	-126.23%	-54.70%
Jasper Therapeutics	N/A	-884.17%	-143.83%

In the previous week, Bolt Biotherapeutics had 1 more articles in the media than Jasper Therapeutics. MarketBeat recorded 1 mentions for Bolt Biotherapeutics and 0 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 0.68 beat Bolt Biotherapeutics' score of 0.00 indicating that Jasper Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Bolt Biotherapeutics	Neutral
Jasper Therapeutics	Positive

Bolt Biotherapeutics currently has a consensus price target of $14.50, suggesting a potential upside of 320.29%. Jasper Therapeutics has a consensus price target of $7.33, suggesting a potential upside of 1,197.48%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Jasper Therapeutics is more favorable than Bolt Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Bolt Biotherapeutics has higher revenue and earnings than Jasper Therapeutics. Jasper Therapeutics is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bolt Biotherapeutics	$7.70M	0.86	-$33.38M	-$16.44	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A

86.7% of Bolt Biotherapeutics shares are owned by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are owned by institutional investors. 9.4% of Bolt Biotherapeutics shares are owned by company insiders. Comparatively, 3.9% of Jasper Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Bolt Biotherapeutics has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.Comparatively, Jasper Therapeutics has a beta of 3.16, meaning that its stock price is 216% more volatile than the broader market.

Summary

Bolt Biotherapeutics beats Jasper Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Bolt Biotherapeutics compare to Neuphoria Therapeutics?

Bolt Biotherapeutics (NASDAQ:BOLT) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Neuphoria Therapeutics has lower revenue, but higher earnings than Bolt Biotherapeutics. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bolt Biotherapeutics	$7.70M	0.86	-$33.38M	-$16.44	N/A
Neuphoria Therapeutics	$1.17M	16.05	-$13.45M	-$6.22	N/A

86.7% of Bolt Biotherapeutics shares are held by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are held by institutional investors. 9.4% of Bolt Biotherapeutics shares are held by company insiders. Comparatively, 1.6% of Neuphoria Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Neuphoria Therapeutics has a net margin of 0.00% compared to Bolt Biotherapeutics' net margin of -611.47%. Neuphoria Therapeutics' return on equity of -38.31% beat Bolt Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bolt Biotherapeutics	-611.47%	-126.23%	-54.70%
Neuphoria Therapeutics	N/A	-38.31%	-28.92%

Bolt Biotherapeutics currently has a consensus price target of $14.50, suggesting a potential upside of 320.29%. Neuphoria Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 101.73%. Given Bolt Biotherapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Bolt Biotherapeutics is more favorable than Neuphoria Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Neuphoria Therapeutics had 2 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 3 mentions for Neuphoria Therapeutics and 1 mentions for Bolt Biotherapeutics. Neuphoria Therapeutics' average media sentiment score of 0.33 beat Bolt Biotherapeutics' score of 0.00 indicating that Neuphoria Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bolt Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neuphoria Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bolt Biotherapeutics has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.Comparatively, Neuphoria Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market.

Summary

Bolt Biotherapeutics and Neuphoria Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Bolt Biotherapeutics compare to Atossa Genetics?

Atossa Genetics (NASDAQ:ATOS) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

Atossa Genetics currently has a consensus target price of $20.33, indicating a potential upside of 768.95%. Bolt Biotherapeutics has a consensus target price of $14.50, indicating a potential upside of 320.29%. Given Atossa Genetics' higher possible upside, equities research analysts plainly believe Atossa Genetics is more favorable than Bolt Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

12.7% of Atossa Genetics shares are owned by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Atossa Genetics has a net margin of 0.00% compared to Bolt Biotherapeutics' net margin of -611.47%. Atossa Genetics' return on equity of -102.99% beat Bolt Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-102.99%	-85.78%
Bolt Biotherapeutics	-611.47%	-126.23%	-54.70%

In the previous week, Atossa Genetics had 3 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 4 mentions for Atossa Genetics and 1 mentions for Bolt Biotherapeutics. Atossa Genetics' average media sentiment score of 0.19 beat Bolt Biotherapeutics' score of 0.00 indicating that Atossa Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atossa Genetics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bolt Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Atossa Genetics has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market. Comparatively, Bolt Biotherapeutics has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.

Bolt Biotherapeutics has higher revenue and earnings than Atossa Genetics. Atossa Genetics is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.11	N/A
Bolt Biotherapeutics	$7.70M	0.86	-$33.38M	-$16.44	N/A

Summary

Atossa Genetics beats Bolt Biotherapeutics on 9 of the 15 factors compared between the two stocks.

Get Bolt Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BOLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BOLT vs. The Competition

Export

Metric	Bolt Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.65M	$3.86B	$7.16B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.32%
P/E Ratio	-0.21	13.06	275.66	26.04
Price / Sales	0.86	1,295.73	609.44	91.76
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	0.25	16.63	10.93	6.31
Net Income	-$33.38M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-3.63%	-2.99%	-2.00%	-1.66%
1 Month Performance	-11.31%	-10.60%	-6.15%	-4.50%
1 Year Performance	-35.03%	19.44%	7.44%	2.06%

Bolt Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BOLT Bolt Biotherapeutics	1.9909 of 5 stars	$3.45 -1.7%	$14.50 +320.3%	-30.4%	$6.65M	$7.70M	N/A	23
RADX Radiopharm Theranostics	2.1845 of 5 stars	$1.52 flat	$11.00 +623.7%	-76.6%	$23.87M	$1.88M	N/A	14	News Coverage
TCRX TScan Therapeutics	2.981 of 5 stars	$0.32 -6.6%	$2.67 +739.9%	-85.3%	$23.05M	$10.32M	N/A	142	News Coverage Gap Up
JSPR Jasper Therapeutics	1.8978 of 5 stars	$0.63 -0.1%	$7.33 +1,072.6%	-76.6%	$20.83M	N/A	N/A	22	High Trading Volume
NEUP Neuphoria Therapeutics	2.4685 of 5 stars	$3.57 -2.2%	$7.00 +96.1%	-76.3%	$19.75M	$1.17M	N/A	8	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BOLT) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bolt Biotherapeutics (BOLT) Competitors

BOLT vs. RADX, TCRX, JSPR, NEUP, and ATOS

How does Bolt Biotherapeutics compare to Radiopharm Theranostics?

Summary

How does Bolt Biotherapeutics compare to TScan Therapeutics?

Summary

How does Bolt Biotherapeutics compare to Jasper Therapeutics?

Summary

How does Bolt Biotherapeutics compare to Neuphoria Therapeutics?

Summary

How does Bolt Biotherapeutics compare to Atossa Genetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLT vs. The Competition

Bolt Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bolt Biotherapeutics (BOLT) Competitors

BOLT vs. RADX, TCRX, JSPR, NEUP, and ATOS

How does Bolt Biotherapeutics compare to Radiopharm Theranostics?

Do institutionals and insiders believe in BOLT or RADX?

Does the media favor BOLT or RADX?

Which has more risk and volatility, BOLT or RADX?

Do analysts prefer BOLT or RADX?

Which has higher earnings and valuation, BOLT or RADX?

Is BOLT or RADX more profitable?

Summary

How does Bolt Biotherapeutics compare to TScan Therapeutics?

Is TCRX or BOLT more profitable?

Does the media prefer TCRX or BOLT?

Which has more risk and volatility, TCRX or BOLT?

Which has stronger earnings and valuation, TCRX or BOLT?

Do analysts rate TCRX or BOLT?

Do insiders and institutionals have more ownership in TCRX or BOLT?

Summary

How does Bolt Biotherapeutics compare to Jasper Therapeutics?

Is BOLT or JSPR more profitable?

Does the media favor BOLT or JSPR?

Do analysts prefer BOLT or JSPR?

Which has preferable earnings and valuation, BOLT or JSPR?

Do institutionals and insiders hold more shares of BOLT or JSPR?

Which has more risk and volatility, BOLT or JSPR?

Summary

How does Bolt Biotherapeutics compare to Neuphoria Therapeutics?

Which has preferable valuation & earnings, BOLT or NEUP?

Do institutionals & insiders hold more shares of BOLT or NEUP?

Is BOLT or NEUP more profitable?

Do analysts rate BOLT or NEUP?

Does the media prefer BOLT or NEUP?

Which has more risk and volatility, BOLT or NEUP?

Summary

How does Bolt Biotherapeutics compare to Atossa Genetics?

Do analysts recommend ATOS or BOLT?

Do insiders & institutionals have more ownership in ATOS or BOLT?

Is ATOS or BOLT more profitable?

Does the media refer more to ATOS or BOLT?

Which has more risk & volatility, ATOS or BOLT?

Which has preferable valuation & earnings, ATOS or BOLT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLT vs. The Competition

Bolt Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools